Artificial Intelligence
Generate Biomedicines
30-Second Executive Brief
Executive Assessment
Generate Biomedicines functions as an emerging institution within Artificial Intelligence, backed by 0% sourcing coverage, though its relative influence is cooling.
- Maintains 1 mapped relationship across the graph
- 0% sourcing coverage across sourced relationships
- Tracked as emerging institution within the Artificial Intelligence category
Executive Snapshot
- Strategic Role
- Emerging Institution
- Sourcing Coverage
- 0%
- Ecosystem Influence
- Regional
- Strategic Momentum
- Decelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 1
- Technology Domains
- 4
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
A Flagship Pioneering-incubated generative biology company that programs protein-based drug modalities using AI, which completed a NASDAQ IPO on February 27, 2026 at $16.00/share, raising $400 million at an approximate $2.04 billion valuation. Prior private backers included Amgen and NVIDIA's venture arm across a $370 million Series B (2021) and $273 million Series C (2023); the stock fell sharply after its public debut, with market cap dropping to roughly $316 million shortly after listing.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Earnings-call mentions
Mentions Amgen, Novartis
“This revenue reflects developments in the ongoing Amgen and Novartis research programs.”
SEC 8-K exhibit (0001193125-26-336462) · Aug 6, 2026
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source
- BioPharma Dive — Generate Biomedicines completes $400M NASDAQ IPOnews
Latest Activity
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Generate Biomedicines — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Generate Biomedicines's Timeline
A sourced, dated history of Generate Biomedicines's key moments — founding to present.
Jan 2018 · Founded
Generate Biomedicines was founded by Flagship Pioneering to apply generative AI to protein-based drug design.
Jan 2023 · $273M Series C
Generate Biomedicines raised a $273 million Series C, with backers including Amgen and NVIDIA's venture arm.
Feb 2026 · NASDAQ IPO raises $400M
Generate Biomedicines priced its IPO at $16.00/share, raising $400 million at an approximate $2.04 billion valuation; shares fell sharply in early trading.